Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2007 2
2008 8
2009 8
2010 11
2011 15
2012 12
2013 21
2014 15
2015 15
2016 10
2017 10
2018 5
2019 3
2020 7
2021 6
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacogenetics to guide cardiovascular drug therapy.
Duarte JD, Cavallari LH. Duarte JD, et al. Nat Rev Cardiol. 2021 Sep;18(9):649-665. doi: 10.1038/s41569-021-00549-w. Epub 2021 May 5. Nat Rev Cardiol. 2021. PMID: 33953382 Free PMC article. Review.
The most common implementation in practice is CYP2C19 genotyping to predict clopidogrel response and assist in selecting antiplatelet therapy after percutaneous coronary intervention. ...Increasing evidence exists on outcomes with genotype-guided cardiovascul …
The most common implementation in practice is CYP2C19 genotyping to predict clopidogrel response and assist in selectin …
Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Karathanos A, Geisler T. Karathanos A, et al. Mol Diagn Ther. 2013 Jun;17(3):123-37. doi: 10.1007/s40291-013-0022-y. Mol Diagn Ther. 2013. PMID: 23588781 Review.
There is a growing degree of evidence supporting high on-treatment platelet reactivity (HPR) as a predictive factor for recurrent ischemic complications. Numerous studies have shown an interindividual variability of responsiveness to clopidogrel and aspirin, which is one o …
There is a growing degree of evidence supporting high on-treatment platelet reactivity (HPR) as a predictive factor for recurrent isc …
Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.
Xie HG, Zou JJ, Hu ZY, Zhang JJ, Ye F, Chen SL. Xie HG, et al. Pharmacol Ther. 2011 Mar;129(3):267-89. doi: 10.1016/j.pharmthera.2010.10.001. Epub 2010 Oct 19. Pharmacol Ther. 2011. PMID: 20965214 Review.
The widespread use of clopidogrel alone or in combination with aspirin has significantly benefited patients with acute coronary syndrome who are managed medically or by percutaneous coronary intervention and stent implantation, greatly improving their survival. Emerging data have …
The widespread use of clopidogrel alone or in combination with aspirin has significantly benefited patients with acute coronary syndrome who …
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G. Giorgi MA, et al. Expert Opin Pharmacother. 2011 Jun;12(8):1285-95. doi: 10.1517/14656566.2011.550573. Epub 2011 Jan 22. Expert Opin Pharmacother. 2011. PMID: 21254864 Review.
This has led to the development of other P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, with different pharmacokinetic characteristics that influence their pharmacodynamics. AREAS COVERED: Clopidogrel response variability is attributable to its complex …
This has led to the development of other P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, with different pharmacokinetic charact …
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.
Khalil BM, Shahin MH, Solayman MH, Langaee T, Schaalan MF, Gong Y, Hammad LN, Al-Mesallamy HO, Hamdy NM, El-Hammady WA, Johnson JA. Khalil BM, et al. Clin Transl Sci. 2016 Feb;9(1):23-8. doi: 10.1111/cts.12383. Epub 2016 Jan 12. Clin Transl Sci. 2016. PMID: 26757134 Free PMC article.
Herein, we investigated genetic and nongenetic factors associated with clopidogrel response in Egyptians. In all, 190 Egyptians with acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), treated with clopidogrel (75 mg/day) for at least a mo …
Herein, we investigated genetic and nongenetic factors associated with clopidogrel response in Egyptians. In all, 190 Egyptian …
Variability of clopidogrel response in patients with type 2 diabetes mellitus.
Hall HM, Banerjee S, McGuire DK. Hall HM, et al. Diab Vasc Dis Res. 2011 Oct;8(4):245-53. doi: 10.1177/1479164111420890. Diab Vasc Dis Res. 2011. PMID: 21933840 Free article. Review.
However, accumulating data suggest a clinically relevant sub-optimal clopidogrel response in some patients with DM. The exact mechanism of these observations is not yet fully understood, but appears to be related to reduced concentrations of circulating clopi …
However, accumulating data suggest a clinically relevant sub-optimal clopidogrel response in some patients with DM. The exact …
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR; ICPC Investigators. Lewis JP, et al. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):203-210. doi: 10.1093/ehjcvp/pvz045. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31504375 Free PMC article.
Patients who carried eight or more risk alleles were significantly more likely to experience CVEs [odds ratio (OR) = 1.78, 95% confidence interval (CI) 1.14-2.76, P = 0.01] and cardiovascular death (OR = 4.39, 95% CI 1.35-14.27, P = 0.01) compared to patients who carried six or f …
Patients who carried eight or more risk alleles were significantly more likely to experience CVEs [odds ratio (OR) = 1.78, 95% confidence in …
Toward Personalized DAPT: Is There an Inter-Manufacturer Difference in Generic Clopidogrel Response?
Hall S, Xia Y, Ahmed H, Iskhakov D, Feit F, Alviar CL, Berger JS, Keller N, Bangalore S. Hall S, et al. J Invasive Cardiol. 2022 Dec;34(12):E873-E878. Epub 2022 Nov 23. J Invasive Cardiol. 2022. PMID: 36416902 Free PMC article.
OBJECTIVE: To compare rates of clopidogrel response among patients receiving medication produced by 2 different manufacturers after acute coronary syndrome (ACS) and/or percutaneous coronary intervention. ...After adjustment for age, sex, body mass index, aspirin re …
OBJECTIVE: To compare rates of clopidogrel response among patients receiving medication produced by 2 different manufacturers …
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
Cavallari LH. Cavallari LH. Expert Rev Cardiovasc Ther. 2017 Aug;15(8):581-589. doi: 10.1080/14779072.2017.1355236. Epub 2017 Jul 19. Expert Rev Cardiovasc Ther. 2017. PMID: 28699807 Free PMC article. Review.
However, there is significant inter-patient variability in clopidogrel response. The CYP2C19 enzyme is involved in the biotransformation of clopidogrel to its pharmacologically active form, and variation in the CYP2C19 gene contributes to clopidogrel respo …
However, there is significant inter-patient variability in clopidogrel response. The CYP2C19 enzyme is involved in the biotran …
129 results